{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T13:48:10Z","timestamp":1761486490908},"reference-count":22,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2000,12,1]],"date-time":"2000-12-01T00:00:00Z","timestamp":975628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2000,12]]},"DOI":"10.1006\/gyno.2000.6006","type":"journal-article","created":{"date-parts":[[2002,9,17]],"date-time":"2002-09-17T18:50:18Z","timestamp":1032288618000},"page":"495-498","source":"Crossref","is-referenced-by-count":18,"title":["A Phase I Trial of a 3-Day Topotecan Q 21 Days for Recurrent Epithelial Cancers of the Ovary, Fallopian Tube, and Peritoneum"],"prefix":"10.1006","volume":"79","author":[{"suffix":"III","given":"John V.","family":"Brown","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"William A.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Rettenmaier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beth Y.","family":"Karlan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Dillman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles W.","family":"Drescher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John Paul","family":"Micha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1006\/gyno.2000.6006_RF1","first-page":"663","article-title":"Clinical trials with topoisomerase 1 inhibitors","volume":"19","author":"Burris","year":"1992","journal-title":"Semin Oncol"},{"key":"10.1006\/gyno.2000.6006_RF2","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/jnci\/85.4.271","article-title":"The current status of comptothecin analogues as anti-tumor agents","volume":"85","author":"Slichenmyer","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1006\/gyno.2000.6006_RF3","first-page":"A769","article-title":"A phase II trial of topotecan as salvage therapy in epithelial ovarian cancer","volume":"14","author":"Armstrong","year":"1995","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1006\/gyno.2000.6006_RF4","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1200\/JCO.1996.14.5.1552","article-title":"Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma","volume":"14","author":"Kudelka","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2000.6006_RF5","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1200\/JCO.1996.14.12.3056","article-title":"Topotecan, an active drug in a second-line treatment of epithelial ovarian cancer: results of a large European phase II study","volume":"14","author":"Creemers","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2000.6006_RF6","unstructured":"Gordon, A, Bookman, M, Malmstrom, Bolis, G, Mangioni, C, Hall, J, Carter, J, Hudson, I, Broom, C: Efficacy of topotecan in advanced epithelial ovarian cancer after failure of platinum and paclitaxel: International Topotecan Study Group Trial. J Clin Oncol15;A763, 1996 (abstract)"},{"key":"10.1006\/gyno.2000.6006_RF7","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1006\/gyno.1997.4787","article-title":"Topotecan in platinum- and paclitaxel-resistant ovarian cancer","volume":"66","author":"Swisher","year":"1997","journal-title":"Gynecol Oncol"},{"key":"10.1006\/gyno.2000.6006_RF8","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1200\/JCO.1998.16.10.3345","article-title":"Topotecan for the treatment of advanced epithelial ovarian cancer: An open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel","volume":"16","author":"Bookman","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2000.6006_RF9","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.1997.15.6.2183","article-title":"Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer","volume":"15","author":"Ten Bokkel Huinink","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2000.6006_RF10","unstructured":"Rowinsky, E, K, Verweij, J, Review of phase I clinical studies with topotecan, Semin Oncol, 24: S20-3, \u2013 S20-10"},{"key":"10.1006\/gyno.2000.6006_RF11","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1093\/jnci\/84.23.1816","article-title":"Activity of topotecan, a new topoisomerase inhibitor against human tumor colony-forming units in vitro","volume":"84","author":"Burris","year":"1992","journal-title":"J Natl Cancer Inst"},{"key":"10.1006\/gyno.2000.6006_RF12","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/BF00685553","article-title":"Evaluation of 9-dimethylaminomethyl-10-hydroxycampothecin against xenografts derived from adult and childhood solid tumors","volume":"31","author":"Houghton","year":"1992","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1006\/gyno.2000.6006_RF13","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1200\/JCO.1992.10.4.647","article-title":"Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor","volume":"10","author":"Rowinsky","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2000.6006_RF14","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1200\/JCO.1998.16.6.2233","article-title":"Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer; a National Cancer Institute of Canada Clinical Trials Group Study","volume":"16","author":"Hoskins","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2000.6006_RF15","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1006\/gyno.1999.5640","article-title":"Lack of efficacy of 24-h infusional topotecan in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Trial","volume":"75","author":"Markman","year":"1999","journal-title":"Gynecol Oncol"},{"key":"10.1006\/gyno.2000.6006_RF16","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1200\/JCO.1995.13.7.1768","article-title":"Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion","volume":"13","author":"Van Warmerdam","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2000.6006_RF17","doi-asserted-by":"crossref","first-page":"605","DOI":"10.7326\/0003-4819-79-4-604","article-title":"Creatinine clearance: bedside estimate","volume":"79","author":"Jelliffe","year":"1973","journal-title":"Ann Intern Med"},{"key":"10.1006\/gyno.2000.6006_RF18","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1182\/blood.V94.3.950.415a18_950_958","article-title":"Differential effects of human granulocyte colony-stimulating factor (hG-CSF) and thrombopoietin on megakaryopoiesis and platelet function in h-G-CSF receptor-transgenic mice","volume":"94","author":"Yang","year":"1999","journal-title":"Blood"},{"key":"10.1006\/gyno.2000.6006_RF19","first-page":"A1424","article-title":"Preliminary results of a Cleveland Clinic Cancer Center Gynecologic Oncology Program phase 2 trial of topotecan (TOPO) administered on a 3-day schedule as salvage therapy of platinum and paclitaxel refractory ovarian cancer (ROC)","volume":"18","author":"Belinson","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2000.6006_RF20","first-page":"706","article-title":"Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer","volume":"20","author":"Grochow","year":"1992","journal-title":"Drug Metab Disp"},{"key":"10.1006\/gyno.2000.6006_RF21","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1200\/JCO.1994.12.9.1946","article-title":"Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity","volume":"12","author":"Stewart","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1006\/gyno.2000.6006_RF22","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1200\/JCO.1996.14.12.3062","article-title":"Phase I and pharmacologic study of topotecan in patients with impaired renal function","volume":"14","author":"O'Reilly","year":"1996","journal-title":"J Clin Oncol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825800960062?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825800960062?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T16:56:13Z","timestamp":1576515373000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825800960062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,12]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2000,12]]}},"alternative-id":["S0090825800960062"],"URL":"https:\/\/doi.org\/10.1006\/gyno.2000.6006","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2000,12]]}}}